news
AstraZeneca Announces Agreements in Principle in Seroquel Product Liability Litigation
9 August 2010 | By AstraZeneca
AstraZeneca reached agreements in principle with attorneys representing approx 17,500 SEROQUEL product liability claimants...
List view / Grid view
AstraZeneca
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
news
AstraZeneca PLC appoints new Non-Executive Director
29 July 2010 | By AstraZeneca
AstraZeneca today announced that Dr Bruce Burlington is to join the Board of Directors as a Non-Executive Director, with effect from 1 August 2010...
news
Advisory Committee Briefing Materials For Brilinta (Ticagrelor) NDA Available On US FDA Web Site
26 July 2010 | By AstraZeneca
The FDA posted briefing materials in advance of 28th July 2010 CRDAC to discuss the New Drug Application (NDA) filed by AstraZeneca...
news
Pharma ‘HTS’ the Mark with Screening
21 July 2010 | By NG Online News
Back in May, it was announced that new stem cell research would reduce the need for animal testing...
news
AstraZeneca and MRC Technology Form Strategic Alliance in Discovery Research, Utilising Shared Compound Libraries
5 July 2010 | By AstraZeneca
AstraZeneca and MRC Technology, announced a new strategic collaboration to share access to...
news
Outsource to Europe
2 July 2010 | By NG Online News
The pharmaceutical industry has faced well documented challenges over the last 12 months, such as the Pfizer...
news
BGMA welcomes EU General Court ruling against AstraZeneca
BGMA welcomes EU General Court ruling that AstraZeneca abused its dominant position by preventing the marketing of generic omeprazole.
news
CRESTOR Patent Upheld By US Court
30 June 2010 | By AstraZeneca
AstraZeneca announced today that Judge Joseph Farnan, Jr., US District Court, District of Delaware, has found that the substance patent protecting CRESTOR (RE37,314 – the ‘314 patent) is valid and enforceable...
news
AstraZeneca and MMV Join Efforts in the Fight Against Malaria
28 June 2010 | By AstraZeneca
AstraZeneca and Medicines for Malaria Venture (MMV) today announced a collaborative agreement designed to identify novel candidate drugs for the treatment of malaria...
article
High content cell based primary screening for oncology targets – a perspective
25 June 2010 | By Peter Alcock, Colin Bath, Carolyn Blackett & Peter B. Simpson, Screening & Assay Sciences, Cancer Bioscience, AstraZeneca Alderley Park
Over the last 15 years, vendors have offered microscope-based instruments capable of producing images of fluorescent labelled components of cells grown in microtitre plates. These instruments are typically bundled with analysis software capable of defining the relative distribution of several fluorescent markers on a cell by cell basis1,2. As the…
article
High Content Analysis Roundtable
29 May 2009 | By
1. How significantly do you feel the Drug Discovery Process has benefited from the application of High Content Analysis techniques? Anthony Davies: Since the mid 1990's High-content analysis (HCA) has primarily been used in the later stages of the pre-clinical drug discovery process. However, as HCA techniques have developed and…
article
Addressing kinetic applications in High Content Screening
29 September 2008 | By
Traditional drug discovery screening assays tend to employ simplistic endpoint assays that often monitor the activity of a single target. While these approaches are amenable to high-throughput screening they provide limited information on how candidate drugs influence complex biological systems that exist in vivo. Such limitations are a contributing factor…
article
Driving lab automation forward
23 November 2007 | By
A round table discussion covering the driving forces behind the integration of automated technology within the pharmaceutical industry, the procedures that are followed when implementing new automated techniques, current areas of drug discovery most benefiting from lab automation, how lab automation advanced the drug discovery marketplace over the last five…
article
Statistical techniques for handling high content screening data
21 September 2007 | By Edward Ainscow, Research Scientist, AstraZeneca
One of the chief incentives for the use of high content screening (HCS) approaches is the data rich return one gets from an individual assay. However, conventional methods for hit selection and activity determination are not well suited to handling multi-parametric data. Tools borrowed from the genomics area have been…
article
Implementation of an enterprise ELN: a case study
21 July 2007 | By Dr. Simon Weston, Programme Delivery Leader, Discovery, AstraZeneca
The paper notebook has played a central role in the recording of the methods and results of scientific research for centuries. It has some strengths: portability, flexibility and (to some degree) incontrovertibility but in an enterprise environment it has many weaknesses. Chief among these is that the vast majority of…
